Increased Neutrophil-To-Lymphocyte Ratio After Neoadjuvant Therapy Is Associated With Worse Survival After Resection of Borderline Resectable Pancreatic Ductal Adenocarcinoma

Surgery - United States
doi 10.1016/j.surg.2016.04.039
Full Text
Abstract

Available in full text

Categories
Surgery
Date
Authors
Publisher

Elsevier BV

Related search

A Systematic Review of Neoadjuvant Therapy Compared to the “Resection First” Approach for Patients With Borderline Resectable Pancreatic Adenocarcinoma

Journal of Cancer Therapy
2014English

An Evaluation of Neoadjuvant Chemoradiotherapy for Patients With Resectable Pancreatic Ductal Adenocarcinoma

HPB Surgery
SurgeryHepatology
2013English

Elevated Neutrophil/Lymphocyte Ratio Is Associated With Appropriate Shock After ICD Implantation

Journal of Clinical and Analytical Medicine
Medicine
2016English

Increased Expression of Plakoglobin Is Associated With Upregulated MAPK and PI3K/AKT Signalling Pathways in Early Resectable Pancreatic Ductal Adenocarcinoma

Oncology Letters
Cancer ResearchOncology
2020English

Increased CDC20 Expression Is Associated With Pancreatic Ductal Adenocarcinoma Differentiation and Progression

Journal of Hematology and Oncology
Cancer ResearchOncologyHematologyMolecular Biology
2012English

Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials

Journal of Clinical Medicine
2020English

Use of Imaging During Symptomatic Follow-Up After Resection of Pancreatic Ductal Adenocarcinoma

Journal of Surgical Research
Surgery
2018English

Heterogeneous Radiological Response to Neoadjuvant Therapy Is Associated With Poor Prognosis After Resection of Colorectal Liver Metastases

European Journal of Surgical Oncology
MedicineOncologySurgery
2019English

Deoxycitidine Kinase Is Associated With Prolonged Survival After Adjuvant Gemcitabine for Resected Pancreatic Adenocarcinoma

Cancer
Cancer ResearchOncology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy